DHRDanaher Corporation
Danaher Corporation (DHR) is a diversified industrial conglomerate with a dominant presence in life sciences tools and services, offering diagnostic equipment, lab instruments, and patient monitoring systems. The company's next catalyst is Oct 27, 2026 — Q3 2026 Earnings Release, which will test its ability to maintain revenue growth and margin stability amid rising input costs and shifting healthcare demand.
- Revenue reached $24.20B in 2026, with a 13.9% net margin and 2.9% YoY revenue growth.
- Free cash flow (TTM) stood at $9.09B, reflecting strong operational efficiency.
- Debt-to-equity of 0.35x suggests a balanced capital structure.
The schedule
- Wed21Oct
Danaher's Q3 2026 earnings will be closely watched for sequential improvements in bioprocessing order books and any updates on China market exposure given ongoing trade policy concerns.
- Tue12Jan
Presentation at the annual J.P. Morgan Healthcare Conference, where market scrutiny on supply chain and BIOSECURE Act compliance costs under President Trump will be in sharp focus.
- Tue9Feb
Q4 2026 results and the introduction of initial FY 2027 guidance, setting the stage for expected baseline growth in bioprocessing and life sciences.
- Tue27Apr
Q1 2027 earnings release, providing an early look at how FY27 guidance is tracking and initial updates on capital deployment initiatives.
- Tue15Jun
A mid-year investor update highlighting Danaher's M&A pipeline and capital allocation strategies to bolster its genomics and advanced therapy portfolios.
- Tue27Jul
Q2 2027 earnings print, highlighting first-half execution against the FY27 roadmap and traction in new product launches.
Past
- Fri20Mar
Actual outcome: Bear · $188.05 at outcome
Danaher's stock fell below the $195.00 bear floor as significant institutional selling by firms like Bank of Nova Scotia and Bamco signaled rising concerns over the BIOSECURE Act's implementation and supply chain risks. The lack of positive momentum from the trade policy update, combined with news of a fiduciary duty investigation, weighed heavily on investor sentiment despite the announcement of the upcoming earnings call.
Danaher's stock fell below the $195.00 bear floor as significant institutional selling by firms like Bank of Nova Scotia and Bamco signaled rising concerns over the BIOSECURE Act's implementation and supply chain risks. The lack of positive momentum from the trade policy update, combined with news of a fiduciary duty investigation, weighed heavily on investor sentiment despite the announcement of the upcoming earnings call.
